{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:31:57Z","timestamp":1793266317477,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.phrs.2026.109669","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:38:24Z","timestamp":1791729504000},"page":"109669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Blockade of mutant RAS oncogenic signaling: A 2026 update"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4139","authenticated-orcid":false,"suffix":"Jr","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.109669_bib1","article-title":"Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS","volume":"173","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.109669_bib2","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/2041104b0","article-title":"An unidentified virus which causes the rapid production of tumours in mice","volume":"204","author":"Harvey","year":"1964","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.109669_bib3","first-page":"735","article-title":"Malignant lymphomas of extrathymic origin induced in rats by murine erythroblastosis virus","volume":"43","author":"Kirsten","year":"1969","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.phrs.2026.109669_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.109669_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/299171a0","article-title":"A transforming gene present in human sarcoma cell lines","volume":"299","author":"Marshall","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.109669_bib6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/303396a0","article-title":"Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1","volume":"303","author":"Hall","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.109669_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1073\/pnas.80.2.383","article-title":"Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line","volume":"80","author":"Shimizu","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.109669_bib8","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1073\/pnas.81.18.5704","article-title":"Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules","volume":"81","author":"Gibbs","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.109669_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.csbj.2019.12.004","article-title":"The current understanding of KRAS protein structure and dynamics","volume":"18","author":"Pantsar","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.phrs.2026.109669_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-291X(03)00323-1","article-title":"Protein prenylation: a pivotal posttranslational process","volume":"303","author":"Roskoski","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2026.109669_bib11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1126\/science.2406906","article-title":"Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins","volume":"247","author":"Milburn","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.109669_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2026.109669_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.109669_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2026.109669_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.109669_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.109669_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"15","key":"10.1016\/j.phrs.2026.109669_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.109669_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.109669_bib20","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1194\/jlr.S092130","article-title":"Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance","volume":"60","author":"Paddock","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2026.109669_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.109669_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"168","key":"10.1016\/j.phrs.2026.109669_bib23","article-title":"Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies","volume":"168","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.109669_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188445","article-title":"SOS GEFs in health and disease","volume":"1874","author":"Baltan\u00e1s","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.109669_bib25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.109669_bib26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","article-title":"Dragging Ras back in the ring","volume":"25","author":"Stephen","year":"2014","journal-title":"Cancer Cell."},{"issue":"170","key":"10.1016\/j.phrs.2026.109669_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"167","key":"10.1016\/j.phrs.2026.109669_bib28","article-title":"EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research","volume":"167","author":"Dong","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.109669_bib29","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.3390\/cancers15205015","article-title":"Targeting KRAS in pancreatic ductal adenocarcinoma: The long road to cure","volume":"15","author":"de Jesus","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2026.109669_bib30","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2026.109669_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/bph.70546","article-title":"Targeting KRAS for cancer therapy","author":"Jia","year":"2026","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.109669_bib32","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.109669_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107060","article-title":"Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis","volume":"200","author":"Chen","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.109669_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2019.118570","article-title":"Therapeutic targeting of RAS: New hope for drugging the \"undruggable\"","volume":"1867","author":"Khan","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell. Res."},{"key":"10.1016\/j.phrs.2026.109669_bib35","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.109669_bib36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a covalent inhibitor of KRAS G12C (AMG 510) for the treatment of solid tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109669_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.phrs.2026.109669_bib38","doi-asserted-by":"crossref","first-page":"W478","DOI":"10.1093\/nar\/gkaf377","article-title":"ProteinsPlus: a publicly available resource for protein structure mining","volume":"53","author":"Ehrt","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2026.109669_bib39","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40265-021-01574-2","article-title":"Sotorasib: First Approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.109669_bib40","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(25)00352-3","article-title":"Health-related quality of life in patients with KRAS(G12C)-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial","volume":"26","author":"Modest","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2026.109669_bib41","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS G12C Inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.109669_bib42","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.109669_bib43","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.109669_bib44","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/pharmaceutics13050653","article-title":"Targeting KRAS in solid tumors: current challenges and future opportunities of novel KRAS inhibitors","volume":"13","author":"Indini","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phrs.2026.109669_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: First Approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.109669_bib46","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109669_bib47","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.109669_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.109669_bib49","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/d41573-026-00145-y","article-title":"RevMed's RAS inhibitor gains landmark FDA approval for pancreatic cancer","volume":"25","author":"Mullard","year":"2026","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.phrs.2026.109669_bib50","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c02314","article-title":"Discovery of daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, noncovalent tri-complex inhibitor for the treatment of patients with multiple RAS-addicted cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109669_bib51","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1021\/acs.jpcb.2c08650","article-title":"Conserved conformational dynamics reveal a key dynamic residue in the gatekeeper loop of human cyclophilins","volume":"127","author":"Ahmed","year":"2023","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.phrs.2026.109669_bib52","doi-asserted-by":"crossref","first-page":"7110","DOI":"10.1128\/jvi.71.9.7110-7113.1997","article-title":"Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions","volume":"71","author":"Dorfman","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.phrs.2026.109669_bib53","doi-asserted-by":"crossref","first-page":"21965","DOI":"10.1074\/jbc.M501623200","article-title":"Structure of human cyclophilin A in complex with the novel immunosuppressant sanglifehrin A at 1.6 A resolution","volume":"280","author":"Kallen","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.109669_bib54","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","article-title":"RMC-6236-001 Investigators, Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer","volume":"394","author":"Wolpin","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.109669_bib55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2605555","article-title":"RASolute 302 Trial Investigators, Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer","volume":"395","author":"O\u2032Reilly","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.109669_bib56","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2026.109669_bib57","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/s12885-025-13868-9","article-title":"PD-1\/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study","volume":"25","author":"Wei","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2026.109669_bib58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12029-025-01194-z","article-title":"Immune-based therapies in pancreatic cancer: a systematic review of ongoing clinical trials (2020-2022)","volume":"56","author":"Hung","year":"2025","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.phrs.2026.109669_bib59","doi-asserted-by":"crossref","DOI":"10.1007\/s00384-024-04790-w","article-title":"Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective","volume":"40","author":"Kaviyarasan","year":"2024","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.phrs.2026.109669_bib60","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826015847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826015847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:36:38Z","timestamp":1793262998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826015847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":60,"alternative-id":["S1043661826015847"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.109669","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blockade of mutant RAS oncogenic signaling: A 2026 update","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.109669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109669"}}